Mendel Biosciences, the Mexico-based biotech startup unveils pioneering AI software designed to accelerate drug development and reshape disease diagnostics.
(Isstories Editorial):- Guadalajara, Jalisco May 7, 2025 (Issuewire.com) – Mendel Biosciences, a biotech company led by Mexican entrepreneur Raul Meza, is pioneering the development of a revolutionary AI-powered software aimed at transforming drug discovery, diagnostics, and personalized medicine. With a mission to accelerate medical research and reduce the time and cost of treatment development, Mendel is introducing innovation to a healthcare system that is increasingly in need of speed, precision, and accessibility.
More on Isstories:
- Your Guide to Choose a Reliable Cosmetic Packaging Supplier: Discovering Why TOPFEELPACK Is the Industry’s Top Choice
- Dr. Jesse R. Wyatt, MD, FAAP, Leads Pediatric Critical Care – Compassionate Medicine in Ventura, CA
- Passionpreneur Publishing announces the global release of Informed Leadership
- Atua AI Deploys Execution Tuning Engines for Stable Multichain Automation
- DJ Free Leonard and Tom Morello Release Powerful New Anthem: “Communities Are Not Commodities”
The software under development by Mendel Biosciences uses artificial intelligence to analyze cellular, molecular, and genomic data in order to identify disease markers, recommend personalized treatments, and predict the efficacy of drug compounds. This approach has the potential to shorten the drug discovery process from years to months while enabling precision in diagnostics and therapeutics across a wide range of conditions, including cancer, rare genetic diseases, and age-related disorders.
“Our goal is to bridge cutting-edge biotechnology with AI to unlock faster and smarter healthcare solutions,” said Raul Meza, founder and director of Mendel Biosciences. “We are building a platform that not only supports pharmaceutical companies in their R&D but also empowers doctors, hospitals, and laboratories with smarter diagnostic tools.”
The company is currently in its early stages and preparing for a round of fundraising to expand its research team and complete the development of its minimum viable product. The software will be offered through a flexible licensing model targeting pharmaceutical companies, research labs, hospitals, and medical specialists.
Beyond commercial potential, Mendel’s work aligns with global priorities in AI and healthcare. Government and institutional support for health innovation and aging research continues to grow, and Mendel aims to contribute meaningfully to the global effort in disease prevention and treatment.
For more information, visit: www.mendelbiosciences.com
Contact Information:
Raul Meza
Founder and Director
Mendel Biosciences
Email: [email protected]
Phone: +52 33 3577 2755
Website: www.mendelbiosciences.com
This article was originally published by IssueWire. Read the original article here.
